BPC-157 and TB-500: two different molecules, two different mechanisms
A structural comparison of BPC-157 and TB-500 — sequence origin, molecular weight, CAS registry numbers, and why they are studied on different pathways despite being sold together.
BPC-157 and TB-500 appear next to each other in almost every research catalog, and are frequently supplied as a combined preparation. The pairing is conventional enough that the two are often discussed as if they were variations on a theme. Structurally they have almost nothing in common.
The basic figures
| BPC-157 | TB-500 | |
|---|---|---|
| Length | 15 amino acids | 43 amino acids (thymosin β4) |
| Molecular formula | C62H98N16O22 | C212H350N56O78S |
| Molecular weight | 1419.5 g/mol | 4963.5 g/mol |
| CAS | 137525-51-0 | 77591-33-4 |
| Origin | Fragment of a gastric protein sequence | Naturally occurring intracellular protein |
TB-500 is roughly three and a half times the mass of BPC-157. They are not analogues, they are not from the same family, and they do not act on the same pathway.
BPC-157
A pentadecapeptide — fifteen residues — corresponding to a partial sequence identified within a protein found in gastric juice. It is a synthetic fragment rather than a naturally circulating signaling molecule in its own right.
In-vitro literature investigates it largely in the context of angiogenesis-related signaling and endothelial behavior, with particular attention to nitric oxide pathway interactions and to growth factor receptor expression in cultured cells. Its small size and its relative stability in acidic conditions are the properties most often cited as distinguishing it from larger peptides.
TB-500
The synthetic form of thymosin β4, a 43-residue protein that occurs naturally inside cells across most tissues. Unlike BPC-157, this is not a designed fragment — it is a molecule that exists in biology, produced synthetically for research use.
Its principal characterized function is actin sequestration. Thymosin β4 binds monomeric G-actin and holds it in a form that is not available for polymerisation into filamentous F-actin. Because actin polymerisation underlies cell shape change and migration, the actin-binding property is the mechanistic anchor for most in-vitro work involving it.
BPC-157 is studied predominantly in the context of signaling pathways and vascular biology. TB-500 is studied predominantly in the context of cytoskeletal dynamics through direct actin binding. Those are different levels of cellular organization, which is the actual reason the two are investigated together rather than as substitutes.
Why they are supplied as a blend
Precisely because the mechanisms are unrelated. A combined preparation is a convenience format for experimental designs examining both pathways in the same system — not a formulation in which one compound potentiates the other in any characterized way.
This has a documentation consequence worth understanding. A blend has no single molecular formula, no single molecular weight, and no CAS registry number of its own, because CAS numbers are assigned to defined substances rather than to mixtures. A blend can only be specified by naming each constituent with its own CAS. Any supplier presenting a single CAS number for a two-peptide blend has made an error somewhere.
Handling implications
The size difference has practical consequences. A 43-residue peptide and a 15-residue peptide do not behave identically in solution, do not necessarily share optimal storage conditions, and will not produce comparable chromatographic profiles. A certificate covering a blend should be legible as to which constituent each result refers to.
This article describes structure and characterized molecular mechanism only. It makes no claim regarding physiological effect, healing, recovery or performance in any organizm. Both compounds are supplied strictly for laboratory and in-vitro research use — not for human or animal use — and no dosing or administration guidance is provided.